ALUR, ALUR-WT · CIK 0001964979 · operating
Allurion Technologies develops a weight loss platform centered on the Allurion Program, a swallowable, procedure-less intragastric balloon designed to treat obesity and overweight conditions. The company's approach combines the physical device with digital health infrastructure, including AI-powered remote patient monitoring, behavior modification programs, secure messaging, and video telehealth capabilities delivered through the Allurion Virtual Care Suite.
The company operates across multiple geographies, with established presence in Spain, France, Turkey, and additional international markets. Allurion maintains a relatively small operational footprint with 134 full-time employees, reflecting its focus on the digital-enabled care model. Revenue streams derive from the sale and deployment of the Allurion Program devices and associated virtual care services, though specific segment breakdowns are not publicly detailed.
Allurion is incorporated in Delaware and headquartered in Natick, Massachusetts. The company is publicly traded on the NYSE.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-11.64 | $-11.64 | -403.9% | |
| 2023 | $-2.31 | $-2.31 | — |